BioXcel Therapeutics (NASDAQ: BTAI)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-09 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.220 | -1.350 | -0.1300 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of BioXcel Therapeutics (NASDAQ: BTAI) through any online brokerage.
Other companies in BioXcel Therapeutics’s space includes: bluebird bio (NASDAQ:BLUE), Centessa Pharmaceuticals (NASDAQ:CNTA), Burning Rock Biotech (NASDAQ:BNR), Eagle Pharmaceuticals (NASDAQ:EGRX) and Adaptimmune Therapeutics (NASDAQ:ADAP).
The latest price target for BioXcel Therapeutics (NASDAQ: BTAI) was reported by Mizuho on Thursday, July 7, 2022. The analyst firm set a price target for 19.00 expecting BTAI to rise to within 12 months (a possible 26.94% upside). 6 analyst firms have reported ratings in the last year.
The stock price for BioXcel Therapeutics (NASDAQ: BTAI) is $14.9679 last updated Today at August 11, 2022, 5:25 PM UTC.
There are no upcoming dividends for BioXcel Therapeutics.
BioXcel Therapeutics’s Q3 earnings are confirmed for Wednesday, November 9, 2022.
There is no upcoming split for BioXcel Therapeutics.
BioXcel Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.